share_log

UBS Adjusts Price Target on LogicBio Therapeutics to $6.30 From $6.10, Maintains Neutral Rating

UBS Adjusts Price Target on LogicBio Therapeutics to $6.30 From $6.10, Maintains Neutral Rating

瑞银将LogicBio Therapeutics的目标股价从6.10美元调整至6.30美元,维持中立评级。
MT Newswires ·  2024/08/12 23:17  · 评级/大行评级

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发